Fan Li1, Zheng Chen2, Yu Yang3, Xianghua Yi4, Yunsheng Yang1, Lanjing Zhang5. 1. Department of Gastroenterology and Hepatology, Chinese PLA General Hospital Beijing, China. 2. Department of Chemical Process Development and Commercialization, Merck & Co. Rahway, NJ. 3. Division of Nephrology, Department of Medicine, University of Maryland School of Medicine Baltimore, MD. 4. Department of Pathology, Tongji Hospital, Tongji University School of Medicine Shanghai, China. 5. Department of Pathology, University Medical Center of Princeton Plainsboro, NJ ; Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University Piscataway, NJ ; Department of Pathology, Robert Wood Johnson Medical School, Rutgers University Piscataway, NJ ; Cancer Institute of New Jersey, Rutgers University Piscataway, NJ.
Abstract
BACKGROUND: The characteristics of pathologically measured (PMS) and endoscopically measured sizes (EMS) of the colorectal polyps (CRPs) is poorly understood, particularly in polypoid unremarkable mucosa (PUM), sessile serrated adenoma (SSA), and high-grade dysplasia (HGD). METHODS: To characterize the discordance and correlation between the PMS and EMS of CRPs including PUM, SSA, HGD, hyperplastic polyp (HP) and adenomas, we conducted this prospective observational study on the polyps collected between August 2012 and December 2013. RESULTS: PMS was significantly smaller than EMS in the 497 qualified CRPs regardless of the sites (left, transverse and right colorectum) or EMS (≥1 cm and <1 cm) subgroups. The PMS and EMS discordance was associated with a diagnosis of HP and adenoma (versus PUM, SSA or HGD), single fragment (versus multiple), 3 of the 8 endoscopists and PMS<1 cm (versus ≥1 cm). Despite a good correlation between EMS and PMS in the adenomas (ĸ=0.626, 95% confidence intervals [CI], 0.505-0.746) and a moderate correlation in the serrated polyps (SPs) including HP and SSA, (ĸ=0.424, 95% CI, 0.244-0.604), 40.4% (23/57) of the adenomas and 63.6% (21/33) of the SPs with EMS≥1 cm might warrant longer follow-up intervals since their PMS were <1 cm. The PMS and EMS had linear correlations except in CRPs with HGD or EMS≥1 cm. CONCLUSIONS: The discordance between PMS and EMS is associated with the pathologic diagnosis, fragment number, endoscopists and PMS, and may lead to different follow-ups in a considerable portion of adenomas and SPs.
BACKGROUND: The characteristics of pathologically measured (PMS) and endoscopically measured sizes (EMS) of the colorectal polyps (CRPs) is poorly understood, particularly in polypoid unremarkable mucosa (PUM), sessile serrated adenoma (SSA), and high-grade dysplasia (HGD). METHODS: To characterize the discordance and correlation between the PMS and EMS of CRPs including PUM, SSA, HGD, hyperplastic polyp (HP) and adenomas, we conducted this prospective observational study on the polyps collected between August 2012 and December 2013. RESULTS:PMS was significantly smaller than EMS in the 497 qualified CRPs regardless of the sites (left, transverse and right colorectum) or EMS (≥1 cm and <1 cm) subgroups. The PMS and EMS discordance was associated with a diagnosis of HP and adenoma (versus PUM, SSA or HGD), single fragment (versus multiple), 3 of the 8 endoscopists and PMS<1 cm (versus ≥1 cm). Despite a good correlation between EMS and PMS in the adenomas (ĸ=0.626, 95% confidence intervals [CI], 0.505-0.746) and a moderate correlation in the serrated polyps (SPs) including HP and SSA, (ĸ=0.424, 95% CI, 0.244-0.604), 40.4% (23/57) of the adenomas and 63.6% (21/33) of the SPs with EMS≥1 cm might warrant longer follow-up intervals since their PMS were <1 cm. The PMS and EMS had linear correlations except in CRPs with HGD or EMS≥1 cm. CONCLUSIONS: The discordance between PMS and EMS is associated with the pathologic diagnosis, fragment number, endoscopists and PMS, and may lead to different follow-ups in a considerable portion of adenomas and SPs.
Authors: Carlos A Rubio; Lars Grimelius; Johan Lindholm; Hans Hamberg; Anja Porwit; Göran Elmberger; Anders Höög; Lena Kanter; Elina Eriksson; Sten Stemme; Abiel Orrego; Leonie Saft; Fredrik Petersson; Manuel De La Torre; Christina Ekström; Kristina Astrom; Asa Rundgren; Miroslav Djokic; E Chandanos; Claes Lenander; Mikael Machado; Per Nilsson; Lars Mattsson Journal: Anticancer Res Date: 2006 Nov-Dec Impact factor: 2.480
Authors: R J Schlemper; R H Riddell; Y Kato; F Borchard; H S Cooper; S M Dawsey; M F Dixon; C M Fenoglio-Preiser; J F Fléjou; K Geboes; T Hattori; T Hirota; M Itabashi; M Iwafuchi; A Iwashita; Y I Kim; T Kirchner; M Klimpfinger; M Koike; G Y Lauwers; K J Lewin; G Oberhuber; F Offner; A B Price; C A Rubio; M Shimizu; T Shimoda; P Sipponen; E Solcia; M Stolte; H Watanabe; H Yamabe Journal: Gut Date: 2000-08 Impact factor: 23.059
Authors: N Gopalswamy; V N Shenoy; U Choudhry; R J Markert; N Peace; M S Bhutani; C J Barde Journal: Gastrointest Endosc Date: 1997-12 Impact factor: 9.427
Authors: S J Winawer; A G Zauber; M J O'Brien; M N Ho; L Gottlieb; S S Sternberg; J D Waye; J Bond; M Schapiro; E T Stewart Journal: N Engl J Med Date: 1993-04-01 Impact factor: 91.245
Authors: S J Winawer; A G Zauber; M N Ho; M J O'Brien; L S Gottlieb; S S Sternberg; J D Waye; M Schapiro; J H Bond; J F Panish Journal: N Engl J Med Date: 1993-12-30 Impact factor: 91.245